Search Result

Results for "

thalassemia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (3) Bcl-2 Family (4) Biochemical Assay Reagents (4) COX (2) DNA Methyltransferase (1) Ferrochelatase (1) Ferroportin (3) Ferroptosis (5) HCV (2) Hepcidin (1) Histone Acetyltransferase (4) Histone Demethylase (1) Histone Methyltransferase (3) Isotope-Labeled Compounds (2) Phosphodiesterase (PDE) (1) Reactive Oxygen Species (ROS) (1) Reference Standards (2) Ser/Thr Protease (6) Small Interfering RNA (siRNA) (1) TGF-beta/Smad (1) Thrombin (1) TMPRSS6 (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (17) Endocrinology (1) Infection (2) Inflammation/Immunology (2) Metabolic Disease (9) Neurological Disease (2)
Oligonucleotides:	siRNA drugs (1) siRNAs (1)

Inhibitors & Agonists

Bibliotecas de Screening

Peptides

Inhibitory Antibodies

Isotope-Labeled Compounds

Oligonucleotides

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-B0568

Deferiprone Maximum Cited Publications 47 Publications Verification	Ferroptosis HCV Apoptosis COX Histone Demethylase	Cardiovascular Disease Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone can inhibit KDM. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .

HY-112220

VIT-2763 5+ Cited Publications	Ferroportin	Metabolic Disease
VIT-2763, an oral ferroportin inhibitor, inhibits hepcidin binding to ferroportin and blocks iron efflux. VIT-2763 has the potential in the treatment of β-thalassemia .

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-139400

Pociredir FTX-6058	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir can induce HbF protein expression in cell and murine models. Pociredir can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-114758

Pyridoxal isonicotinoyl hydrazone 4 Publications Verification	Biochemical Assay Reagents Ferrochelatase	Cardiovascular Disease
Pyridoxal isonicotinoyl hydrazone is an orally active and lipophilic iron-specific chelator that acts as a non-competitive inhibitor of ferrochelatase (FECH) by binding iron ions. Pyridoxal isonicotinoyl hydrazone disrupts heme biosynthesis, leading to reduced FECH stability and increased protoporphyrin IX (PPIX) accumulation. Pyridoxal isonicotinoyl hydrazone is promising for research of iron-overload diseases (e.g., β-thalassemia) .

HY-131060

CN128 hydrochloride CN328	Ferroptosis	Others
CN128 hydrochloride (CN328) is an orally active and selective iron chelator. CN128 is used for the research of β-thalassemia .

HY-108260

Deferitrin GT-56-252	Ferroptosis	Cardiovascular Disease
Deferitrin (GT-56-252), a desferrithiocin (DFT) analogue, is an orally active trident iron chelator. Deferitrin is used for chronic iron overload due to transfusional therapy. Deferitrin has the potential for beta-thalassemia major .

HY-126301

DMT1 blocker 1 3 Publications Verification	Ferroportin	Metabolic Disease
DMT1 blocker 1 is an orally active blocker of divalent metal transporter 1 (DMT1) with an IC₅₀ of 0.64 μM. DMT1 blocker 1 inhibits intestinal cell absorption of non-heme iron, thereby alleviating iron overload by blocking the DMT1 transporter. DMT1 blocker 1 demonstrates significant efficacy in rodent models of acute iron hyperabsorption. DMT1 blocker 1 is useful for studying iron overload disorders such as hereditary hemochromatosis and thalassemia .

HY-139400A

Pociredir hydrochloride FTX-6058 hydrochloride	Histone Methyltransferase	Cardiovascular Disease
Pociredir (FTX-6058) hydrochloride is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). Pociredir hydrochloride can induce HbF protein expression in cell and murine models. Pociredir hydrochloride can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia .

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

HY-B0568R

Deferiprone (Standard)	Reference Standards Ferroptosis HCV Apoptosis COX	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Endocrinology Cancer
Deferiprone (Standard) is the analytical standard of Deferiprone. This product is intended for research and analytical applications. Deferiprone is a potent, orally active, brain-penetrant, cell-penetrant, skin-permeable, free iron chelating agent. Deferiprone inhibits the proliferation and migration, and stimulates apoptosis in tumor cell. Deferiprone has antianemic, neuroprotective, anti-inflammatory, antioxidant, and antidotal activity. Deferiprone can be used in cancer, cardiovascular disease, infection, inflammation, and neurological disease study .

HY-178486

SH6	Histone Acetyltransferase	Cardiovascular Disease
SH6 is a transcription factor ZBTB7A degrader. SH6 is promising for research of β-hemoglobinopathies such as sickle cell disease (SCD) and β-thalassemia .

HY-16912

Petadeferitrin SP-420	Ferroptosis	Metabolic Disease
Petadeferitrin (SP-420) is a tridentate iron chelator belonging to the class of iron chelators, with orally activity. Petadeferitrin can be used in research related to β-thalassemia .

HY-W015881

Dimebutic acid NSC-16045; NSC-741804	Bcl-2 Family	Cardiovascular Disease
Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid can be used in the study of β-thalassemia and sickle cell disease .

HY-147278

Manusiran Divesiran; SLN124	Ser/Thr Protease Small Interfering RNA (siRNA) TMPRSS6	Cardiovascular Disease
Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .

HY-130136A

TMPRSS6-IN-1 TFA	Ser/Thr Protease	Others
TMPRSS6-IN-1 (TFA) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .

HY-W767164

Deferiprone O-β-D-glucuronide sodium	Biochemical Assay Reagents	Cardiovascular Disease
Deferiprone O-β-D-glucuronide sodium is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide sodium can be used to investigate its ability to reduce iron burden in patients with β-thalassemia .

HY-130136

TMPRSS6-IN-1	Ser/Thr Protease	Others
TMPRSS6-IN-1 (compound 8) is a potent inhibitor of TMPRSS6 (Matriptase-2), belonging to TTSPs (transmembrane serine protease). TMPRSS6, is a type II TTSP, the genetic reduction of which will improve symptoms of hemochromatosis and beta thalassemia in mice .

HY-P11260

MD5	Ser/Thr Protease Thrombin	Metabolic Disease
MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC₅₀ for recombinant human TMPRSS6 protein of 22 nM and a K_i of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC₅₀ of 352 nM and a K_i of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with K_i of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia) .

HY-114643

(Rac)-Tovinontrine (Rac)-IMR-687	Phosphodiesterase (PDE)	Cardiovascular Disease
(Rac)-Tovinontrine ((Rac)-IMR-687) is a phosphodiesterase 9 (PDE9) inhibitor that increases cyclic guanosine monophosphate (cGMP) levels. (Rac)-Tovinontrine is promising for research of thalassemia .

HY-163819

WIZ degrader 3	Histone Acetyltransferase	Cardiovascular Disease
WIZ degrader 3 (Compound 29) is a degrader for widely interspaced zinc finger motifs (WIZ), with an AC₅₀ of 6.4 nM. WIZ degrader 3 induces the expression of fetal hemoglobin (HbF), with an EC₅₀ of 45 nM. WIZ degrader 3 can be used for the research of blood disorders, such as sickle cell disease and β- thalassemia .

HY-P991637

REGN7999	Ser/Thr Protease	Metabolic Disease
REGN7999 is a monoclonal antibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .

HY-163820

WIZ degrader 4	Histone Acetyltransferase	Others
WIZ degrader 4 (Example 1) is a WIZ degrader with an AC₅₀ value of 160 nM. WIZ degrader 4 can be used to investigate sickle cell disease (SCD) and thalassemia .

HY-163824

WIZ degrader 7	Histone Acetyltransferase	Others
WIZ degrader 7 (Example 16) is a WIZ degrader with an IC₅₀ value of < 0.01 μM. WIZ degrader 7 can be used to investigate sickle cell disease (SCD) and thalassemia .

HY-160078

Deferiprone O-β-D-glucuronide	Biochemical Assay Reagents	Metabolic Disease
Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide can be used to investigate its ability to reduce iron burden in patients with β-thalassemia .

HY-169761

(rac)-dWIZ-1	Histone Methyltransferase	Cardiovascular Disease
WIZ-IN-1 (Example 2) is a Wiz inhibitor (DC₅₀: 0.36 μM). WIZ-IN-1 can be used for research of inherited blood disorders (e.g., hemoglobinopathies, e.g., beta- hemoglobinopathies), such as sickle cell disease and beta-thalassemia .

HY-W015881A

Dimebutic acid sodium NSC-16045 sodium; NSC-741804 sodium	Bcl-2 Family	Cardiovascular Disease
Dimebutic acid sodium is an orally active short-chain fatty acid. Dimebutic acid sodium stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid sodium prolongs red blood cell survival. Dimebutic acid sodium exhibits toxicity in rats. Dimebutic acid sodium can be used in the study of β-thalassemia and sickle cell disease .

HY-167814S

Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt	Isotope-Labeled Compounds Biochemical Assay Reagents	Metabolic Disease
Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt is the deuterium labeled Deferiprone O-β-D-glucuronide (HY-160078). Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide shows the capability of reducing the iron burden in patients with β-thalassemia .

HY-W015881R

Dimebutic acid (Standard) NSC-16045 (Standard); NSC-741804 (Standard)	Reference Standards Bcl-2 Family	Cardiovascular Disease
Dimebutic acid (Standard) is an analytical standard of Dimebutic acid (HY-W015881). This product is intended for research and analytical applications. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid can be used in the study of β-thalassemia and sickle cell disease .

HY-W699526

Dimebutic acid-d6 NSC-16045-d₆; NSC-741804-d₆	Isotope-Labeled Compounds Bcl-2 Family	Cardiovascular Disease
Dimebutic acid-d₆ (NSC-16045-d₆; NSC-741804-d₆) is the deuterium labeled Dimebutic acid (HY-W015881). Dimebutic acid is a fatty acid derivative. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid is used in the study of β-thalassemia and sickle cell disease .

HY-183852

GSK3830052	DNA Methyltransferase	Cancer
GSK3830052 is a selective DNA methyltransferase 1 (DNMT1) inhibitor. GSK3830052 can be used to study cancer, sickle cell disease, β-thalassemia, and other diseases associated with DNMT1 inhibition .

HY-P992451

RLYB331 KY1066	Ser/Thr Protease Hepcidin Reactive Oxygen Species (ROS) Apoptosis	Cardiovascular Disease
RLYB331 (KY1066) is a is a monoclonal antibody targeting Matriptase-2 (TMPRSS6) . RLYB331 binds to the serine protease active site of matriptase-2, blocking protease activity to increase hepcidin expression. RLYB331 reduces iron overload, inhibits α-aggregates, reduces ROS, inhibits apoptosis, and enhances erythroid differentiation. RLYB331 ameliorates ineffective erythropoiesis in β-thalassemic mouse models. RLYB331 can be used for the research of β-thalassemia .

Cat. No.	Nombre del producto

HY-L171

Anti-Hematopathy Compound Library	4,172 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs. MCE designs a unique collection of 4,172 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Anti-Hematopathy Compound Library

4,172 compounds

Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.

MCE designs a unique collection of 4,172 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.

Cat. No.	Nombre del producto	Target	Research Area

HY-P10272

Rusfertide PTG-300	Ferroportin	Others
Rusfertide is a peptide mimetic of natural hepcidin, which targets and degrades ferroportin, reduces serum iron and transferrin-saturation, and thus regulates the production of red blood cells. Rusfertide ameliorates the polycythemia vera, β-thalassemia and hereditary hemochromatosis .

HY-P11260

MD5	Ser/Thr Protease Thrombin	Metabolic Disease
MD5 is a selective TMPRSS6 mimetic peptide inhibitor with an IC₅₀ for recombinant human TMPRSS6 protein of 22 nM and a K_i of 3.4 nM. MD5 exhibits the significantly reduced inhibitory effect on Matriptase, with an IC₅₀ of 352 nM and a K_i of 99.2 nM. MD5 exhibits good target specificity and only has a weak inhibitory effect on thrombin (Thrombin), with K_i of 120 nM. MD5 demonstrates good initial drugability and can be used for the study of iron overload diseases (such as hereditary hemochromatosis, β-thalassemia) .

Cat. No.	Nombre del producto	Target	Research Area	Image

HY-P99720A

Luspatercept (mIgG2a) RAP-536	TGF-beta/Smad	Metabolic Disease
Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects .

HY-P991637

REGN7999	Ser/Thr Protease	Metabolic Disease
REGN7999 is a monoclonal antibody that inhibits TMPRSS6. REGN7999 inhibits TMPRSS6 activity, preventing Hemojuvelin (HJV) lysis, thereby enhancing BMP6-HJV signaling and increasing serum hepcidin. REGN7999 ameliorates iron overload and impaired erythropoiesis in a β-thalassemia mouse model by inhibiting TMPRSS6 activity. REGN7999 is indicated for research in β-thalassemia .

HY-P992451

RLYB331 KY1066	Ser/Thr Protease Hepcidin Reactive Oxygen Species (ROS) Apoptosis	Cardiovascular Disease
RLYB331 (KY1066) is a is a monoclonal antibody targeting Matriptase-2 (TMPRSS6) . RLYB331 binds to the serine protease active site of matriptase-2, blocking protease activity to increase hepcidin expression. RLYB331 reduces iron overload, inhibits α-aggregates, reduces ROS, inhibits apoptosis, and enhances erythroid differentiation. RLYB331 ameliorates ineffective erythropoiesis in β-thalassemic mouse models. RLYB331 can be used for the research of β-thalassemia .

Cat. No.	Nombre del producto	Chemical Structure

HY-167814S

Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt
Deferiprone-d3 3-O-Beta-D-Glucuronide Sodium Salt is the deuterium labeled Deferiprone O-β-D-glucuronide (HY-160078). Deferiprone O-β-D-glucuronide is a novel orally active iron chelator. Deferiprone O-β-D-glucuronide shows the capability of reducing the iron burden in patients with β-thalassemia .

HY-W699526

Dimebutic acid-d6
Dimebutic acid-d₆ (NSC-16045-d₆; NSC-741804-d₆) is the deuterium labeled Dimebutic acid (HY-W015881). Dimebutic acid is a fatty acid derivative. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid is used in the study of β-thalassemia and sickle cell disease .

Dimebutic acid-d6

Dimebutic acid-d₆ (NSC-16045-d₆; NSC-741804-d₆) is the deuterium labeled Dimebutic acid (HY-W015881). Dimebutic acid is a fatty acid derivative. Dimebutic acid is an orally active short-chain fatty acid. Dimebutic acid stimulates fetal globin production and alters the balance of Bcl family proteins. Dimebutic acid prolongs red blood cell survival. Dimebutic acid exhibits toxicity in rats. Dimebutic acid is used in the study of β-thalassemia and sickle cell disease .

Cat. No.	Nombre del producto		Classification

HY-147278

Manusiran Divesiran; SLN124		siRNAs siRNA drugs
Manusiran (Divesiran) is a GalNac-siRNA targeting liver and transmembrane serine protease 6 (Serine protease 6). Manusiran increases hepatic Hepcidin synthesis and plasma levels by silencing TMPRSS6, a negative regulator of hepcidin production, and limits the availability of iron required for erythropoiesis. Combined use of Manusiran with Deferiprone (HY-B0568) reduces ineffective erythropoiesis and hepatic iron overload in a mouse model of β-thalassemia. Manusiran can be used for research on polycythemia vera, type 1 hereditary hemochromatosis, and β-thalassemia .

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent: